De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Nova Leap Health Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Chris Dobbin
Algemeen directeur
US$271.7k
Totale compensatie
| Percentage CEO-salaris | 22.2% |
| Dienstverband CEO | 8.9yrs |
| Eigendom CEO | 10.1% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 8yrs |
Recente managementupdates
Recent updates
Risks Still Elevated At These Prices As Nova Leap Health Corp. (CVE:NLH) Shares Dive 27%
Sep 12
Nova Leap Health Corp.'s (CVE:NLH) 33% Price Boost Is Out Of Tune With Revenues
Jun 08Should Shareholders Reconsider Nova Leap Health Corp.'s (CVE:NLH) CEO Compensation Package?
May 31Nova Leap Health Corp. (CVE:NLH) Looks Just Right With A 28% Price Jump
Mar 23Market Participants Recognise Nova Leap Health Corp.'s (CVE:NLH) Revenues
Jan 06Nova Leap Health Corp. (CVE:NLH) Investors Are Less Pessimistic Than Expected
Jul 29Does Nova Leap Health (CVE:NLH) Have A Healthy Balance Sheet?
Feb 22Calculating The Intrinsic Value Of Nova Leap Health Corp. (CVE:NLH)
Aug 17Nova Leap Health (CVE:NLH) Is Carrying A Fair Bit Of Debt
May 14Estimating The Intrinsic Value Of Nova Leap Health Corp. (CVE:NLH)
Oct 22Nova Leap Health (CVE:NLH) Strong Profits May Be Masking Some Underlying Issues
Mar 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$126k |
| Mar 31 2024 | n/a | n/a | -US$285k |
| Dec 31 2023 | US$272k | US$60k | -US$1m |
| Sep 30 2023 | n/a | n/a | -US$1m |
| Jun 30 2023 | n/a | n/a | -US$902k |
| Mar 31 2023 | n/a | n/a | -US$743k |
| Dec 31 2022 | US$259k | US$59k | -US$836k |
| Sep 30 2022 | n/a | n/a | -US$592k |
| Jun 30 2022 | n/a | n/a | US$119k |
| Mar 31 2022 | n/a | n/a | US$489k |
| Dec 31 2021 | US$292k | US$63k | US$2m |
| Sep 30 2021 | n/a | n/a | US$4m |
| Jun 30 2021 | n/a | n/a | US$3m |
| Mar 31 2021 | n/a | n/a | US$2m |
| Dec 31 2020 | US$248k | US$63k | US$1m |
| Sep 30 2020 | n/a | n/a | -US$278k |
| Jun 30 2020 | n/a | n/a | -US$789k |
| Mar 31 2020 | n/a | n/a | -US$313k |
| Dec 31 2019 | US$235k | US$193k | -US$1m |
| Sep 30 2019 | n/a | n/a | -US$730k |
| Jun 30 2019 | n/a | n/a | -US$1m |
| Mar 31 2019 | n/a | n/a | -US$922k |
| Dec 31 2018 | US$249k | US$176k | -US$961k |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$1m |
| Mar 31 2018 | n/a | n/a | -US$1m |
| Dec 31 2017 | US$95k | US$95k | -US$852k |
Compensatie versus markt: De totale vergoeding ($USD 271.70K ) Chris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 177.89K ).
Compensatie versus inkomsten: De vergoeding van Chris is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Chris Dobbin (49 yo)
8.9yrs
Tenure
US$271,704
Compensatie
Mr. Christopher Donald Dobbin, also known as Chris, C.P.A., C.A., ICD D., serves as the Chief Executive Officer and President of Nova Leap Health Corp. and served as its Chief Financial Officer until Octob...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 8.9yrs | US$271.70k | 10.09% $ 2.1m | |
| Independent Director | 8.9yrs | US$27.17k | 2.58% $ 533.7k | |
| Independent Chairman of the Board | 8.9yrs | US$45.28k | 3.45% $ 714.5k | |
| Independent Director | 3.6yrs | US$22.64k | 0.079% $ 16.3k | |
| Independent Director | 3.5yrs | US$22.64k | geen gegevens | |
| Independent Director | 7.1yrs | US$27.17k | 4.32% $ 893.8k |
8.0yrs
Gemiddelde duur
50yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NLH wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).